Late breaking oral communication presentation of top line data of randomized, double-blind, multicenter, placebo-controlled Phase 2b/3 study ANAVEX®2-73-AD-004 for the treatment of early Alzheimer’s disease at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022, December 1, 2022, at 4:30pm PT in San Francisco, CA.
Nearing the enrollment completion of the randomized, placebo-controlled EXCELLENCE Phase 2/3 study ANAVEX®2-73-RS-003 for the treatment of pediatric patients with Rett syndrome.
Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX®2-73 for the treatment of Fragile X syndrome in a double-blind, randomized, placebo-controlled Phase 2/3 development program.
Upcoming Pipeline expansion of the ANAVEX platform using gene biomarkers of response and applying precision medicine for treatment of neurological disorders with high unmet medical need are expected:
Meeting with FDA to discuss ANAVEX®2-73 Parkinson’s disease program including pivotal Phase 3 study.
Planned initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical study.
Planned initiation of a Phase 2/3 clinical trial for the treatment of a new rare-disease indication.
Planned initiation of ANAVEX®3-71 Phase 2 clinical trial for schizophrenia.
- https://finance.yahoo.com/news/anavex-life-sciences-reports-fiscal-120000029.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.